Neuraxis, Inc. NRXS
7.56
(0.19)
(2.45%)
as of 25 Sep
- Market cap
- $97.3M
- P/E
- 0.0×
Follow NRXS
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (153.96%) | (269.21%) | (315.62%) | (3,433.40%) |
+8 more TTM periods Free account |
|
| (98.96%) | (137.13%) | (154.37%) | (240.65%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(132.43%) | (149.62%) | (285.58%) | (432.27%) | |
Average Days of Receivables |
29.72 | 32.82 | 20.01 | 11.78 | |
Free Cash Flow per Share |
(0.47) | (0.55) | (0.73) | (0.64) | |
Free Cash Flow |
(5.64) | (6.06) | (6.60) | (6.28) | |
Capital Expenditures |
(0.02) | — | (0.17) | (0.03) | |
Piotroski F-Score |
4.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(37.33%) | (47.24%) | (76.91%) | (93.92%) | |
Accounts Receivable Turnover |
18.94 | 13.62 | 16.21 | 41.74 | |
Accounts Payable Turnover |
1.22 | 1.53 | 1.53 | 0.58 | |
Inventory Turnover |
3.76 | 4.66 | 3.74 | 8.10 | |
Average Days of Payables |
376.31 | 173.63 | 90.39 | 601.37 | |
Days of Inventory on Hand |
131.82 | 135.52 | 166.71 | 74.83 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.94% | 11.10% | 13.83% | 18.19% | |
Selling, General and Administrative Expense of Revenue |
218.14% | 243.84% | 289.77% | 291.24% | |
Share Based Compensation of Revenue |
24.21% | 19.16% | 16.72% | 13.08% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.75 | 0.75 | 0.75 | |
Depreciation/Fixed assets |
1.12 | 1.03 | 0.79 | 0.49 | |
Capex/Depreciation |
(0.27) | 0.00 | (2.89) | (0.60) | |
Revenue per Share |
0.44 | 0.39 | 0.39 | 0.34 | |
Operating CF per Share |
(0.46) | (0.55) | (0.71) | (0.63) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.01 | |
Net Profit Margin |
(159.01%) | (188.57%) | (241.37%) | (247.62%) |
Columns are period end dates